Zenas BioPharma (ZBIO) Accumulated Expenses (2023 - 2026)

Zenas BioPharma's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 80.08% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 80.08% YoY), while the FY2025 annual figure was $13.1 million, down 66.78% from the prior year.
• Accumulated Expenses was $5.6 million for Q1 2026 at Zenas BioPharma, down from $13.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $39.4 million in Q4 2024 to a low of $5.6 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $18.4 million across 4 years, with a median of $15.2 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses soared 127.5% in 2024, then slumped 80.08% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $17.3 million in 2023, then surged by 127.5% to $39.4 million in 2024, then tumbled by 66.78% to $13.1 million in 2025, then sank by 57.05% to $5.6 million in 2026.
• The last three Accumulated Expenses figures came in at $5.6 million (Q1 2026), $13.1 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.